Results 211 to 220 of about 42,178 (305)

Enablers, Challenges, and Lessons Learned From a Digital Health Intervention (Sehatmandi App) in Afghanistan: Qualitative Study.

J Med Internet Res
Sayani S, Jabeen F, Samnani S, Muqeet A, Khan A, Delawar G, Subzlani M.   +6 more
europepmc   +1 more source

Design and Application of a Core Competency Training Program for New Nurse Managers Based on the Kemp Model From Role Theory Perspective: A Pilot Study. [PDF]

J Nurs Manag
Wang T, Zhang R, Li J, Yao F, Wu F, Cai W.   +5 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

The impact of new package managers on the library dependency ecosystem. [PDF]

PeerJ Comput Sci
Rahkema K, Pfahl D, Ramler R.
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Doing more with less: the impact of the COVID-19 pandemic on Latino-serving community-based organizations. [PDF]

BMC Public Health
De Trindad Young ME, Castañeda-Castañeda B, Juarez-Cahue D, Garibay K, Chamie G, Marquez C, Marson K, Yen IH.   +7 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Healthcare stakeholders' perspectives on coordinating cancer diagnosis in Chile, Colombia, and Ecuador. [PDF]

Rev Panam Salud Publica
Oturai O, Mogollón-Pérez AS, Eguiguren P, Torres Castillo AL, Peralta-Chiriboga AA, Rubio-Valera M, Dias S, Jervelund SS.   +7 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Research and training fellowships as a mechanism for building research capacity in social care: an evaluation of a capacity-building programme in England

Zhang W, Towers A, Charles A, Trapp O, Abrahamson V, Allan S, Smith N, Hashem F, Mikelyte R.   +8 more
europepmc   +1 more source